A healthy immune system is potentially equipped to detect and eradicate cancer cells. Unfortunately, established tumours can deploy a number of strategies to evade and defeat immune attack. We are targeting these inhibitory mechanisms and, at the same time, stimulating the immune system to enable a strong and effective reponse against the tumour.
FasT Biopharma Ltd was established in 2016 to address new targets in immuno-oncology (IO). We are funded by Alderley Park Ventures and we are based in Alderley Park and in Oxford. Our lead product is an optimised antibody against a key IO target